Novartis International AG Says Glivec Has Potential to Treat PAH; Drug Did Not Reach Statistical Significance In Main Target

ZURICH, Oct 8 (Reuters) - Novartis AG's cancer drug Glivec had the potential to treat a rare heart and lung condition in a mid-stage trial, but did not reach its main target in the study.